Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Carcinoma, Transitional Cell 15Neoplasms 14Ovarian Neoplasms 13Carcinoma, Renal Cell 13Urinary Bladder Neoplasms 12Carcinoma, Merkel Cell 12Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Melanoma 7Stomach Neoplasms 6Recurrence 5Breast Neoplasms 5Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Lymphoma, Non-Hodgkin 2Kidney Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Ovarian Epithelial 2Uveal Melanoma 1Urothelial Cancer 1

Interventions

nintedanib 1avelumab 1DOXO-EMCH 1BN 80927 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Malignant Solid Tumour × avelumab × Clear all
NCT02923466 2022-04-27

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

Vyriad, Inc.

Phase 1 Completed
76 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡